India Drug Maker Fears Of Pricing Rules Not Reflected By Stock Market
This article was originally published in PharmAsia News
Although the pharmaceutical industry is expressing concerns about India's new policy of setting key drug prices, the stock markets appear to believe other factors will have a greater and offsetting effect.
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
From enforced detention to hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.